In a report released today, Jason Bednar from Piper Sandler reiterated a Buy rating on NovoCure (NVCR – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $15.24.
Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Cooper Co, and Merit Medical Systems. According to TipRanks, Bednar has an average return of -3.8% and a 42.40% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NovoCure with a $33.50 average price target, which is an 119.82% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $49.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $83.60 and a one-year low of $10.87. Currently, NovoCure has an average volume of 1.33M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NovoCure (NVCR) Company Description:
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More on NVCR:
